⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13309236 | 1.00 | — | — | |
| SCHEMBL3387123 | 1.00 | — | — | |
| SCHEMBL14435544 | 1.00 | — | — | |
| SCHEMBL21396628 | 0.87 | — | — | |
| SCHEMBL6357085 | 0.87 | — | — | |
| SCHEMBL13451412 | 0.84 | — | — | |
| SCHEMBL6692240 | 0.84 | KDM4E (0.32) | — | |
| SCHEMBL21185140 | 0.84 | — | — | |
| SCHEMBL851839 | 0.80 | — | — | |
| SCHEMBL21787940 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10059955-A | — | — | None | — | — | JP | disclosed |
| CN-115304568-B | Asymmetric synthesis method of 6-azidomethylene-1-aryl-3-oxabicyclo [3,1,0] hex-2-one | 扬州大学 | 2024-03-26 | — | — | CN | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-115304568-A | Asymmetric synthesis method of 6-azidomethylene-1-aryl-3-oxabicyclo [3,1,0] hexan-2-ketone | 扬州大学 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-114805167-A | Preparation method of brivaracetam | 上海博志研新药物技术有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2018107056-A1 | 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-14 | — | — | WO | disclosed |
| US-9595734-B2 | Non-aqueous liquid electrolyte for secondary battery and secondary battery | FUJIFILM CORPORATION (JP) | 2017-03-14 | — | — | US | disclosed |
| US-9595734-B2 | Non-aqueous liquid electrolyte for secondary battery and secondary battery | FUJIFILM CORPORATION (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20140234729-A1 | NON-AQUEOUS LIQUID ELECTROLYTE FOR SECONDARY BATTERY AND SECONDARY BATTERY | FUJIFILM CORPORATION (JP) | 2014-08-21 | — | — | US | disclosed |
| WO-2006048152-A2 | DICARBOXAMIDE DERIVATIVES AND THEIR USE AS FACTOR XA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| EP-1080085-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO 3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054324-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO[3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| JP-H1059955-A | 2-OXO-3-OXIBICYCLO(3,1,0)HEXANE DERIVATIVE AND ITS PRODUCTION | DAISO CO LTD | 1998-03-03 | — | — | JP | disclosed |
| US-4720556-A | 3-oxabicyclo-(3,1,0)-hexan-2-ones | ROUSSEL UCLAF (FR) | 1988-01-19 | — | — | US | disclosed |
| US-4398032-A | REDUCTION WITH SELECTIVE REDUCING AGENT | SHELL OIL COMPANY (US) | 1983-08-09 | — | — | US | disclosed |
| US-4375557-A | REDUCTION OF DIHALO-OXABICYCLO(3.1.0)HEXAN-2-ONE | SHELL OIL COMPANY (US) | 1983-03-01 | — | — | US | disclosed |
| US-4346038-A | Oxabicyclo[3.1.0]hexan-2-ones | SHELL OIL COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| US-4346038-A | Oxabicyclo[3.1.0]hexan-2-ones | SHELL OIL COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| EP-0004493-A1 | Ethers whose organic moieties have asymmetric atoms, methods for their preparation and their use for the resolution of alcohols, phenols or certain compounds with a lactone structure | ROUSSEL-UCLAF (FR) | 1979-10-03 | — | — | EP | disclosed |